Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

SKYE : 5.22 (-4.04%)
Skye Bioscience to Announce Third Quarter 2024 Results

SKYE : 5.22 (-4.04%)
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

SKYE : 5.22 (-4.04%)
Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

SKYE : 5.22 (-4.04%)
MarketBeat Week in Review – 10/7 - 10/11

Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings

NFLX : 762.81 (+0.97%)
NVDA : 139.67 (+2.66%)
META : 568.67 (+1.43%)
AAPL : 222.91 (+0.41%)
SKYE : 5.22 (-4.04%)
XOM : 118.27 (-0.29%)
NU : 14.56 (+1.32%)
CCL : 22.54 (+2.88%)
DAL : 58.57 (+2.95%)
WMT : 83.58 (+1.37%)
PLTR : 50.96 (+23.06%)
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar

Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.

SKYE : 5.22 (-4.04%)
NVO : 109.21 (-0.46%)
LLY : 805.01 (-0.14%)
3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.

NVDA : 139.67 (+2.66%)
SKYE : 5.22 (-4.04%)
NVO : 109.21 (-0.46%)
SPWR : 0.1228 (-5.47%)
SCWO : 1.4500 (+3.57%)
RENT : 10.96 (+11.31%)
2 Growth Stocks With 20% to 40% Upside in 2024

Both of these companies’ innovative products present excellent long-term opportunities for investors seeking growth in the stock market.

SKYE : 5.22 (-4.04%)
$SPX : 5,771.89 (+1.04%)
INTU : 616.65 (-0.38%)
Skye Bioscience Announces $40 Million Private Placement Equity Financing

Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB:...

SKYE : 5.22 (-4.04%)
Skye Bioscience to Present at Oppenheimer Investor Conference

San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization...

SKYE : 5.22 (-4.04%)

Barchart Exclusives

Should You Buy Meta Platforms Stock After Earnings?
Despite crushing broader market returns in the past two years, Meta Platforms stock still trades at a reasonable valuation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar